Has anyone switched to tenecteplase as your primary thrombolytic agent for acute ischemic stroke? If so, did you take any steps to address the fact that there is a prominent dosing table on the inside of the box for myocardial infarction? See https://www.tnkase.com/dosing-and-administration/dosing-guidelines.html
The dosing for stroke (off-label) is very different than the tiered dosing strategy for MI (the only labeled indication for tenecteplase). We will of course have the correct ordered dose in the EHR, along with an independent double check, but wondering if anyone made any interventions beyond education.
Thank you!
Avo Arikian, PharmD
Medication Safety Coordinator
Clovis Community Medical Center